Need context from a QBank here. Our card is consistent with AMBOSS’ claim.
AMBOSS in the linked article directly state: “The indications listed below are consistent with the 2023 ADA guidelines. The 2021 USPSTF guideline recommends screening in adults aged 35–70 years with overweight or obesity.”
Followed by the first indication listed: “All individuals ≥ 35 years of age;
Patients < 35 years of age who: Are overweight or obese AND have ≥ 1 additional risk factor for T2DM” (etc. etc.)